U.S. Markets closed

Sorrento Therapeutics, Inc. (SRNE)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.05+0.05 (+2.50%)
At close: 4:00PM EDT

2.05 0.00 (0.00%)
After hours: 6:12PM EDT

People also watch
NKRGLSADXSTGTXLBIO
Full screen
Previous Close2.00
Open2.00
Bid1.50 x 20000
Ask2.15 x 200
Day's Range2.00 - 2.05
52 Week Range1.50 - 8.35
Volume248,912
Avg. Volume1,131,120
Market Cap156.84M
Beta1.89
PE Ratio (TTM)-1.61
EPS (TTM)-1.27
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Trade prices are not sourced from all markets
  • Accesswire4 days ago

    Today's Research Reports on Stocks to Watch: Sorrento Therapeutics and Omeros Corporation

    NEW YORK, NY / ACCESSWIRE / July 17, 2017 / Sorrento Therapeutics had a big insider purchase revealed last week that helped drive share prices higher. Omeros Corporation also saw big gains after announcing ...

  • Capital Cube20 days ago

    ETFs with exposure to Sorrento Therapeutics, Inc. : June 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sorrento Therapeutics, Inc. Here are 5 ETFs with the largest exposure to SRNE-US. Comparing the performance and risk of Sorrento Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswire21 days ago

    Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain

    SAN DIEGO, June 29, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company's Investigational New Drug Application (IND) for Resiniferatoxin (RTX), a non-opioid, TRPV1 agonist that selectively targets afferent nerve activation involved in chronic pain states. Sorrento intends to promptly initiate a multicenter, Phase 1b clinical trial of RTX administered by epidural injection for the treatment of intractable pain associated with cancer.